Compare Novartis AG (NVS) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $235.36 (market cap $44.37B). The key difference: Novartis AG is far larger — about 6.5× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Novartis AG pays a 3.17% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| NVS | TTWO | |
|---|---|---|
Market Cap | $290.25B | $44.37B |
Sector | Health | Media |
52-Week High | $168.62 | $262.29 |
52-Week Low | $113.50 | $189.69 |
Enterprise Value | $330.27B | $45.34B |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Take-Two Interactive (TTWO) trades at $235.93, down 0.31% on the day, with a neutral technical signal despite recent earnings beats. The company shows strong revenue growth to $5.63 billion in 2025 but faces profitability challenges with a net income margin of -4.48%. Analyst sentiment remains overwhelmingly positive with a 78.95% buy rating and a consensus price target of $302.50, driven by anticipation for Grand Theft Auto VI.
The outlook hinges on GTA VI execution, with potential for significant upside if launch succeeds, but risks include persistent negative cash flow from operations and high debt levels. Investors should weigh strong analyst confidence against fundamental weaknesses in profitability and cash generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
